Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333940 | 0.93 | PTGES (0.44) | PTGESSMN1; SMN2THRBPOLBTP53 | |
| SCHEMBL335343 | 0.92 | THRB (0.44) | SMN1; SMN2THRBPOLBTP53MAPT | |
| SCHEMBL334350 | 0.90 | PTGES (0.52) | PTGESPPARGPPARAMEN1KMT2A | |
| SCHEMBL333812 | 0.85 | ALOX5 (0.43) | SMN1; SMN2THRBPOLBTP53MAPT | |
| SCHEMBL4224224 | 0.85 | SMN1; SMN2 (0.39) | PTGESSMN1; SMN2THRBPOLBTP53 | |
| SCHEMBL334190 | 0.84 | SCN9A (0.45) | SMN1; SMN2THRBPOLBTP53MAPT | |
| SCHEMBL333479 | 0.83 | TP53 (0.52) | SMN1; SMN2THRBPOLBTP53MAPT | |
| SCHEMBL334099 | 0.83 | ALOX5 (0.45) | SMN1; SMN2THRBPOLBTP53MAPT | |
| SCHEMBL333728 | 0.82 | ALOX5 (0.45) | PTGESSMN1; SMN2THRBTP53MAPT | |
| SCHEMBL333467 | 0.82 | SMN1; SMN2 (0.44) | PTGESSMN1; SMN2THRBPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | PTGES 28/4885SMN1; SMN2 3779/4885THRB 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.